---
layout: post
title: "Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability"
date: 2026-02-05 18:57:42 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-00521
original_published: 2022-01-13 00:00:00 +0000
significance: 8.00
---

# Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 13, 2022 00:00 UTC
**Document Number:** 2022-00521

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Becton, Dickinson & Company (BD) for the BioGX SARS-CoV-2 Reagents for BD MAX System, Boston Medical Center for the BMC-CReM COVID-19 Test, and Akron Children's Hospital for the Akron Children's Hospital SARS-CoV-2 Assay. FDA revoked these Authorizations on December 8, 2021, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, which include an explanation of the reasons for each revocation, are reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/13/2022-00521/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devices-for-detection)
- API: https://www.federalregister.gov/api/v1/documents/2022-00521

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
